"Driven by nearly 20 years of pioneering research and innovation, StemCells is a recognized leader when it comes to expertise, scientific achievement and intellectual property in the field of stem cell biology."


Approximate Financial Snapshot as of 10/31/12
Shares Outstanding 30.4M  
52 Wk Hi/Lo 2.67/


Market Cap $63.3M
Recent Price $2.08




Join the SmallCapReview mailing list



StemCells (STEM)


"StemCells, Inc. is applying its scientific and industry leadership in stem cell biology to discover, develop and commercialize breakthrough therapeutics and enabling tools and technologies for use in stem cell-based research and drug discovery."


StemCells (STEM) a biopharmaceutical company, engages in the research, development, and commercialization of stem cell therapeutics, and related tools and technologies for academia and industry. 

It develops cell-based therapeutics for the central nervous system and liver. The company's product candidate HuCNS-SC cells has completed a Phase I clinical trial for the treatment of infantile and late infantile neuronal ceroid lipofuscinosis, a neurodegenerative disorder of the brain; and completed a Phase I clinical trial for the treatment of Pelizeaus-Merzbacher disease, a fatal myelination disorder in the brain. It also engages in developing HuCNS-SC cells, which are in Phase I/II clinical trial for the treatment of chronic spinal cord injury; and HuCNS-SC cells that are in Phase I/II clinical trial for the treatment of dry age-related macular degeneration.

In addition, the company identifies and develops human liver engrafting cells for a range of liver diseases; and is involved in developing and commercializing applications of its technologies to enable stem cell-based research. Further, it markets a range of proprietary cell culture products under the SC Proven brand, including iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff N2B27, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents under the SC Proven brand comprising STEM24, STEM101, STEM121, and STEM123 for cell detection, isolation, and characterization. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories.

STEM Investor Highlights

  • Partnered with R Biomedical, an Edinburgh, UK-based biomedical company, to develop and commercialize a range of cell lines and reagents to facilitate human induced pluripotent stem (iPS) cell-based research for regenerative medicine applications. The first product under the partnership, an "ultra-primary" human fibroblast cell line from which researchers can generate iPS cell lines, was launched today under the SC Proven brand.

  • StemCells has a broad and expanding clinical development program for its HuCNS-SC cells. The Company has ongoing Phase I/II clinical trials in chronic thoracic spinal cord injury and dry age-related macular degeneration, and is planning for a controlled Phase II study in Pelizaeus-Merzbacher Disease.

  • Announced the issuance of U.S. Patent Number 8,283,164 titled "Liver engrafting cells, assays, and uses thereof." The patent broadly covers purified populations of human liver cells, including the Company's human liver engrafting cells (hLEC). hLEC cells were first isolated by Company researchers in the late 1990s, and Company scientists have repeatedly demonstrated the cells' engraftment and robust bioactivity in vivo and that they are expandable.

  • In October 2011, StemCells formed a wholly-owned subsidiary to focus on both the therapeutic and research tool applications of its hLEC technologies and to serve as an investment vehicle for those interested in a "pure play" liver cell company.

Recent News and Press Releases

StemCells, Inc. Partners With R Biomedical to Develop and Commercialize Reagents for Human iPS Cell Research

StemCells, Inc. to Present at 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum

StemCells, Inc. Adds Eliseo Salinas to Advise on Product Development Strategy for Its Proprietary Human Neural Stem Cells

FDA Considering Faster Pathway for Treatments of Deadly or Debilitating Diseases

StemCells, Inc. Awarded Broad U.S. Patent Covering Expandable Liver Cells

For the latest Quote and News on STEM Click Here.

Three Month Chart


Martin McGlynn - President and Chief Executive Officer

Martin McGlynn joined StemCells, Inc. in January of 2001 as President and Chief Executive Officer and was elected to our Board of Directors on February 6, 2001. Mr. McGlynn has spent several decades in the life sciences industry in Europe, Canada and the United States. He began his career with Becton Dickinson, Ireland Ltd., and spent eight years in manufacturing operations. He joined Abbott Labs in 1977 where he held positions as General Manager, Abbott Ireland Ltd., President and General Manager of Abbott Canada Ltd. and Vice President of Abbott International Ltd. In 1990, he joined the BOC Group as President of Anaquest, Inc., a global leader in anesthesia and acute care pharmaceuticals headquartered in New Jersey. Mr. McGlynn joined the biotech industry in 1994 when he became President and Chief Executive Officer of Pharmadigm, Inc., a private, venture capital-backed company engaged in the research and development of a new class of anti-inflammatory agents. Mr. McGlynn is a native of Dublin, Ireland. He holds a Bachelor of Commerce degree from University College, Dublin. He is a former member of the Board of Directors of the Confederation of Irish Industries (CII) and the Pharmaceutical Manufacturers Association of Canada (PMAC), and currently serves as a member of the Board of the Alliance for Regenerative Medicine (ARM).

Ann Tsukamoto PhD. - Executive Vice President, Research and Development

Ann Tsukamoto was appointed Executive Vice President, Research and Development in September 2008. She previously served as Vice President, Research and Development. Dr. Tsukamoto has more than 20 years experience in stem cell biology and was a co-discoverer of the human hematopoietic stem cell while at SyStemix, Inc., and played a leading role in the launch of the clinical research program for the hematopoietic stem cell. Under her direction at StemCells, Inc., the scientific team isolated the human neural stem cell, a population of human liver engrafting cells and a candidate pancreas stem cell. Dr. Tsukamoto received her PhD from the University of California, Los Angeles and did postdoctoral research with Dr. Harold Varmus at the University of California, San Francisco where she worked on the wnt-1 gene, which is a key player in the stem cell self-renewal pathway. Dr. Tsukamoto is an inventor on six issued US patents related to the human hematopoietic stem cell.

Rodney Young - Chief Financial Officer and Vice President, Finance and Administration

Rodney Young joined StemCells, Inc. in September 2005. He has overall responsibility for corporate financial management, financial reporting and controls, investor relations and information technology. Prior to joining StemCells, Mr. Young was Chief Financial Officer and a director of a private pharmaceutical company focused on developing drugs for pediatric indications, where he was responsible for all financial and administrative functions. Before joining the biotechnology industry, Mr. Young was Managing Director and head of health care corporate finance in Europe for SG Cowen Securities, and prior to that, he spent more than a decade at Lehman Brothers, where he was a senior investment banker in both the health care and mergers & acquisitions groups. Mr. Young earned his BA and MBA degrees from the University of Chicago.

SEC Filings

STEM filings with the SEC can be found here.



7707 Gateway Boulevard
Suite 140
Newark, CA 94560
Phone: 510-456-4000
Fax: 510-456-4001 feature stock reports are intended to be stock ideas, not recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company website and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our website. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

Copyright SmallCapReview. All rights reserved. SCR is not a Registered Broker/Dealer or Financial Advisor. All materials presented on our website and individual reports released to the public through this website, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility, particularly small-caps. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SmallCapReview may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our website or within our reports  In order to be in full compliance with the Securities Act of 1933, Section 17(b), SCR will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SmallCapReview website. SmallCapReview has not been compensated for its efforts with regards to StemCells.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: and/or the National Association of Securities Dealers (NASD) at: . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its website.